DUBLIN, Ohio--(BUSINESS WIRE)--Aug. 2, 2006--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced financial results for the second quarter of 2006 and for the six-month period ended June 30, 2006. For the second quarter of 2006, Neoprobe reported a net loss of $861,000 or $0.01 share compared to a net loss of $1.3 million or $0.02 per share for the second quarter in 2005. For the six months ended June 30, 2006, Neoprobe reported a net loss of $1.8 million or $0.03 per share compared to a net loss of $2.3 million or $0.04 per share for the same period in 2005. The net loss for the second quarter of 2006 included $348,000 in non-cash charges compared to total non-cash charges of $322,000 for the second quarter of 2005. The net loss for the six-month period ended June 30, 2006 included $745,000 in non-cash charges compared to total non-cash charges of $775,000 for the same period in 2005.
